Yuan Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuan Dong has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Jinbo Cheng
College of Life & Environmental Science, Center on Translational Neuroscience, Minzu University of China, Beijing, China
2 shared publications - Lin Hou
Department of Biochemistry and Molecular Biology of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, P.R. China
1 shared publication - Xiaoheng Li
Beijing Institute for Brain Disorders, Capital Medical University, Beijing 100069, China
1 shared publication Xiaoqi Yu
Neuropsychiatry Research Institute, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China
1 shared publication- Yajin Liao
NHC Key Laboratory of Neurodegenerative diseases (University of South China), 421001 Hengyang, Hunan, China
1 shared publication Yi Jia
School of Basic Medical Sciences, Qingdao University, Qingdao, China
1 shared publication
Latest Publications
- Open Access
- 8 January 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 15, 1298166
Research progress on the cannabinoid type-2 receptor and Parkinson’s disease
Parkinson’s disease (PD) is featured by movement impairments, including tremors, bradykinesia, muscle stiffness, and imbalance. PD is also associated with many non-motor symptoms, such as cognitive impairments, dementia, and mental disorders. Previous studies identify the associations between PD progression and factors such as α-synuclein aggregation, mitochondrial dysfunction, inflammation, and cell death. The cannabinoid type-2 receptor (CB2 receptor) is a transmembrane G-protein-coupled receptor and has been extensively studied as part of the endocannabinoid system. CB2 receptor is recently emerged as a promising target for anti-inflammatory treatment for neurodegenerative diseases. It is reported to modulate mitochondrial function, oxidative stress, iron transport, and neuroinflammation that contribute to neuronal cell death. Additionally, CB2 receptor possesses the potential to provide feedback on electrophysiological processes, offering new possibilities for PD treatment. This review summarized the mechanisms underlying PD pathogenesis. We also discussed the potential regulatory role played by CB2 receptor in PD.
- 8 January 2024
- Published by Frontiers Media SA in Frontiers in Aging Neuroscience
- Vol. 15, 1298166
Open AccessResearch progress on the cannabinoid type-2 receptor and Parkinson’s disease
Parkinson’s disease (PD) is featured by movement impairments, including tremors, bradykinesia, muscle stiffness, and imbalance. PD is also associated with many non-motor symptoms, such as cognitive impairments, dementia, and mental disorders. Previous studies identify the associations between PD progression and factors such as α-synuclein aggregation, mitochondrial dysfunction, inflammation, and cell death. The cannabinoid type-2 receptor (CB2 receptor) is a transmembrane G-protein-coupled receptor and has been extensively studied as part of the endocannabinoid system. CB2 receptor is recently emerged as a promising target for anti-inflammatory treatment for neurodegenerative diseases. It is reported to modulate mitochondrial function, oxidative stress, iron transport, and neuroinflammation that contribute to neuronal cell death. Additionally, CB2 receptor possesses the potential to provide feedback on electrophysiological processes, offering new possibilities for PD treatment. This review summarized the mechanisms underlying PD pathogenesis. We also discussed the potential regulatory role played by CB2 receptor in PD.
- Open Access
- 28 January 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (3) , 558
Drug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target?
Alzheimer’s disease (AD) is one of the most common causes of dementia. Its pathogenesis is characterized by the aggregation of the amyloid-β (Aβ) protein in senile plaques and the hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Current medications for AD can provide temporary help with the memory symptoms and other cognitive changes of patients, however, they are not able to stop or reverse the progression of AD. New medication discovery and the development of a cure for AD is urgently in need. In this review, we summarized drugs for AD treatments and their recent updates, and discussed the potential of microglia induced neuroinflammation as a target for anti-AD drug development.
- 28 January 2019
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 20 (3) , 558
Open AccessDrug Development for Alzheimer’s Disease: Microglia Induced Neuroinflammation as a Target?
Alzheimer’s disease (AD) is one of the most common causes of dementia. Its pathogenesis is characterized by the aggregation of the amyloid-β (Aβ) protein in senile plaques and the hyperphosphorylated tau protein in neurofibrillary tangles in the brain. Current medications for AD can provide temporary help with the memory symptoms and other cognitive changes of patients, however, they are not able to stop or reverse the progression of AD. New medication discovery and the development of a cure for AD is urgently in need. In this review, we summarized drugs for AD treatments and their recent updates, and discussed the potential of microglia induced neuroinflammation as a target for anti-AD drug development.
- Open Access
- 10 February 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (2) , 248
The Function of the Mitochondrial Calcium Uniporter in Neurodegenerative Disorders
The mitochondrial calcium uniporter (MCU)—a calcium uniporter on the inner membrane of mitochondria—controls the mitochondrial calcium uptake in normal and abnormal situations. Mitochondrial calcium is essential for the production of adenosine triphosphate (ATP); however, excessive calcium will induce mitochondrial dysfunction. Calcium homeostasis disruption and mitochondrial dysfunction is observed in many neurodegenerative disorders. However, the role and regulatory mechanism of the MCU in the development of these diseases are obscure. In this review, we summarize the role of the MCU in controlling oxidative stress-elevated mitochondrial calcium and its function in neurodegenerative disorders. Inhibition of the MCU signaling pathway might be a new target for the treatment of neurodegenerative disorders.
- 10 February 2017
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (2) , 248
Open AccessThe Function of the Mitochondrial Calcium Uniporter in Neurodegenerative Disorders
The mitochondrial calcium uniporter (MCU)—a calcium uniporter on the inner membrane of mitochondria—controls the mitochondrial calcium uptake in normal and abnormal situations. Mitochondrial calcium is essential for the production of adenosine triphosphate (ATP); however, excessive calcium will induce mitochondrial dysfunction. Calcium homeostasis disruption and mitochondrial dysfunction is observed in many neurodegenerative disorders. However, the role and regulatory mechanism of the MCU in the development of these diseases are obscure. In this review, we summarize the role of the MCU in controlling oxidative stress-elevated mitochondrial calcium and its function in neurodegenerative disorders. Inhibition of the MCU signaling pathway might be a new target for the treatment of neurodegenerative disorders.